Archives
Itraconazole: Triazole Antifungal Agent and CYP3A4 Inhibi...
Itraconazole: Triazole Antifungal Agent and CYP3A4 Inhibitor for Candida Research
Executive Summary: Itraconazole (SKU: B2104) is a triazole antifungal compound that inhibits fungal cytochrome P450 enzymes, notably CYP3A4, and demonstrates robust in vitro and in vivo efficacy against Candida spp. biofilms (IC50 = 0.016 mg/L) [DOI]. It is cell-permeable, insoluble in water and ethanol but readily soluble in DMSO (≥8.83 mg/mL), and stable at -20°C for several months. Itraconazole extends beyond antifungal action, inhibiting hedgehog signaling and angiogenesis, making it valuable for pharmacokinetic and pathway studies [D-Lin]. APExBIO supplies validated, research-grade Itraconazole for reproducible and sensitive Candida assays [APExBIO].
Biological Rationale
Candida albicans is an opportunistic fungal pathogen capable of forming biofilms that confer intrinsic resistance to antifungal agents [DOI]. The incidence of systemic and oral candidiasis is increasing, especially among immunocompromised populations. Biofilm formation involves complex, highly organized microbial communities and is a major factor in clinical treatment failure. Current antifungal options include azoles, echinocandins, and polyenes, but resistance is a growing global health concern [DOI]. Targeted agents such as Itraconazole are required for effective management and research modeling of Candida biofilms and drug interaction phenomena.
Mechanism of Action of Itraconazole
Itraconazole is a triazole antifungal agent. Its principal mechanism is the inhibition of fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase (CYP51), crucial for ergosterol biosynthesis. This disrupts fungal cell membrane integrity and function. Itraconazole is both a substrate and a potent inhibitor of human CYP3A4, leading to drug interaction risks and unique research applications. The compound undergoes hepatic oxidative metabolism, producing hydroxylated, keto, and N-dealkylated derivatives, some of which have equal or greater inhibitory potency. Additionally, Itraconazole inhibits the hedgehog signaling pathway and angiogenesis, expanding its use in cell signaling and pharmacological studies [Cytochrome].
Evidence & Benchmarks
- Itraconazole demonstrates in vitro IC50 of 0.016 mg/L against Candida species biofilms under standard bioassay conditions (RPMI 1640 medium, 35°C, 48h) (Shen 2025, DOI).
- Itraconazole treatment in murine models of disseminated candidiasis leads to significant reduction of fungal burden and improved survival rates (intraperitoneal administration, 5 mg/kg, daily for 7 days) (Shen 2025, DOI).
- Itraconazole potently inhibits CYP3A4 in human liver microsomes with established use as a positive control in CYP3A-mediated metabolism studies (D-Lin MC3).
- Stock solutions are stable for several months at -20°C, and optimal solubility in DMSO is achieved at concentrations ≥8.83 mg/mL, with improved dissolution following warming to 37°C and ultrasonic agitation (APExBIO).
- Itraconazole inhibits the hedgehog signaling pathway and angiogenesis, supporting research in cancer and developmental biology (NHS-LC-Biotin).
Applications, Limits & Misconceptions
Itraconazole is validated for use in:
- Antifungal drug screening, especially against Candida glabrata and Candida albicans biofilms.
- CYP3A4 inhibition assays and drug-drug interaction modeling.
- Cellular signaling pathway studies (hedgehog, angiogenesis).
- Pharmacokinetic profiling and metabolism research workflows.
This article extends previous summaries, such as this solutions-oriented protocol guide by providing updated IC50 benchmarks, clarified solubility and stability guidance, and new evidence on biofilm resistance models.
Common Pitfalls or Misconceptions
- Itraconazole is insoluble in water and ethanol; use DMSO for stock solutions to ensure experimental reproducibility (APExBIO).
- It should not be used for Gram-negative or Gram-positive bacterial infections—activity is strictly antifungal.
- Resistance in Candida biofilms may require higher concentrations or combination therapy (Shen 2025, DOI).
- Itraconazole is a strong inhibitor of CYP3A4, potentially confounding metabolism studies if not properly controlled.
- Do not store stock solutions at room temperature; stability is compromised outside -20°C conditions.
Workflow Integration & Parameters
For optimal integration in antifungal or cell-based assays:
- Prepare stock solutions in DMSO at ≥8.83 mg/mL.
- Facilitate dissolution by warming to 37°C and ultrasonication.
- Store aliquots at -20°C; avoid repeated freeze-thaw cycles.
- Apply validated concentrations: 0.01–10 μM for cell-based studies; follow published protocols for in vivo dosing (e.g., 5 mg/kg IP for murine models).
- Monitor for CYP3A4-related drug interactions in co-incubation or combination therapy studies.
This workflow guidance builds upon experimental troubleshooting detailed in this comparative analysis, clarifying parameters for reproducible results in Candida and CYP3A4 research settings.
Conclusion & Outlook
Itraconazole (B2104) is a benchmark triazole antifungal and CYP3A4 inhibitor, integral for advanced Candida research, antifungal drug interaction studies, and pathway-focused experiments [Itraconazole product page]. Supplied by APExBIO, it offers robust, validated performance for sensitive laboratory workflows. Future directions include further elucidation of its signaling effects and overcoming emerging biofilm resistance, as highlighted in recent translational studies. For expanded context, see this review, which our article updates with new mechanistic and workflow evidence.